HIV Highlights-Comorbidity, Coinfection - HIV

Highlights of Atlanta 2013: Coinfections and Comorbidities

In this CME-certified slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review the most clinically relevant data presented at the 2013 Conference on Retroviruses and Opportunistic Infections.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Faculty: Joseph J. Eron, Jr. MD, William G. Powderly MD, Kimberly Y. Smith MD, MPH

Released: 5/3/2013
Highlights of Atlanta 2013: Coinfections and Comorbidities

In this downloadable slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review key studies on coinfection and comorbidities in HIV infection from the 2013 Conference on Retroviruses and Opportunistic Infections.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/22/2013
COAT Study: Increased Mortality When Starting ART Early During Induction Therapy for Cryptococcal Meningitis in Antiretroviral-Naive HIV-Infected Patients

High incidence of early deaths in patients initiating first-line ART during antifungal induction therapy for CM vs deferring ART until ≥ 5 weeks after CM diagnosis.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/14/2013
COSMOS: High SVR Rates With 12 Weeks of Simeprevir Plus Sofosbuvir With or Without Ribavirin in Patients With GT 1 HCV Monoinfection, Mild to Moderate Fibrosis, and Previous Null Response to PegIFN/RBV

SVR8 attained by 93% to 96% of patients in the 12-week arms; both regimens safe and generally well tolerated, with anemia and grade 3/4 bilirubin increases in the RBV-containing treatment arms only.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
Dose-Finding Study Suggests Dosing of Rifampin Could Be Increased in Patients With Newly Diagnosed TB

In this small dose-finding study, rifampin doses up to 35 mg/kg were safe, well tolerated, and more active than the currently used 10-mg/kg dose in patients with newly diagnosed TB.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
High SVR Rate Following 12-Week Treatment of Acute Genotype 1 HCV Infection With Telaprevir Plus Peginterferon/Ribavirin in HIV-Coinfected MSM

In a single-center pilot study, a 12-week course of telaprevir and peginterferon/ribavirin in MSM with acute genotype 1 HCV infection was associated with an SVR24 rate of 79%.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
HIV/HCV-Coinfected MSM Exhibit High Reinfection Rates With HCV Genotypes Other Than That of Primary Infection

Preferential HCV reinfection of HIV-infected MSM with genotypes other than the primary infection suggests original infection confers partial immunity to similar genotype.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
STARTVerso 4: Faldaprevir Plus Peginterferon/Ribavirin Associated With High Early Virologic Response Rate in HIV/Genotype 1 HCV–Coinfected Patients

In interim analysis, 82% of HCV treatment–naive patients and 91% of previous relapsers coinfected with HIV attained HCV RNA below lower limit of quantitation with faldaprevir plus peginterferon/ribavirin at Week 12 of therapy.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
Random Biopsy Increases Number of High-Grade Squamous Intraepithelial Lesions Detected by High-Resolution Anoscopy and Improves Diagnostic Rate in Patients With Suspected Anal Squamous Cell Cancer

Increased risk of HSILs detected by random biopsy was associated with greater number of HSILs detected by standard biopsy, whereas oncogenic HPV infection, provider/venue were associated with increased risk of HSILs detected by random or standard biopsy.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
RIFAQUIN Trial: High-Dose Rifapentine 1200 mg Once Weekly Plus Moxifloxacin in Continuation Phase Safe, Noninferior to Control in Patients With New Pulmonary TB

A 4-month regimen with twice-weekly rifapentine 900 mg plus moxifloxacin in the continuation phase was safe but demonstrated inferior efficacy compared with an isoniazid-containing control regimen.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Other Sites

Topics

Educational Formats

Program Resources

User Resources

PDF
Video

Help
Site Tour
RSS

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

HIV Highlights-Comorbidity, Coinfection Source: 2013 Conference on Retroviruses and Opportunistic Infections*
Conference Program HIV Highlights-ART • Capsule Summaries (14) • Downloadable slideset • CCO Slideset (CME) HIV Highlights-Comorbidity, Coinfection • Capsule Summaries (15) • Downloadable slideset • CCO Slideset (CME)	Latest Content 10 of 17 Shown Highlights of Atlanta 2013: Coinfections and Comorbidities In this CME-certified slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review the most clinically relevant data presented at the 2013 Conference on Retroviruses and Opportunistic Infections. Source: 2013 Conference on Retroviruses and Opportunistic Infections Faculty: Joseph J. Eron, Jr. MD, William G. Powderly MD, Kimberly Y. Smith MD, MPH Released: 5/3/2013 Highlights of Atlanta 2013: Coinfections and Comorbidities In this downloadable slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review key studies on coinfection and comorbidities in HIV infection from the 2013 Conference on Retroviruses and Opportunistic Infections. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/22/2013 COAT Study: Increased Mortality When Starting ART Early During Induction Therapy for Cryptococcal Meningitis in Antiretroviral-Naive HIV-Infected Patients High incidence of early deaths in patients initiating first-line ART during antifungal induction therapy for CM vs deferring ART until ≥ 5 weeks after CM diagnosis. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/14/2013 COSMOS: High SVR Rates With 12 Weeks of Simeprevir Plus Sofosbuvir With or Without Ribavirin in Patients With GT 1 HCV Monoinfection, Mild to Moderate Fibrosis, and Previous Null Response to PegIFN/RBV SVR8 attained by 93% to 96% of patients in the 12-week arms; both regimens safe and generally well tolerated, with anemia and grade 3/4 bilirubin increases in the RBV-containing treatment arms only. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 Dose-Finding Study Suggests Dosing of Rifampin Could Be Increased in Patients With Newly Diagnosed TB In this small dose-finding study, rifampin doses up to 35 mg/kg were safe, well tolerated, and more active than the currently used 10-mg/kg dose in patients with newly diagnosed TB. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 High SVR Rate Following 12-Week Treatment of Acute Genotype 1 HCV Infection With Telaprevir Plus Peginterferon/Ribavirin in HIV-Coinfected MSM In a single-center pilot study, a 12-week course of telaprevir and peginterferon/ribavirin in MSM with acute genotype 1 HCV infection was associated with an SVR24 rate of 79%. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 HIV/HCV-Coinfected MSM Exhibit High Reinfection Rates With HCV Genotypes Other Than That of Primary Infection Preferential HCV reinfection of HIV-infected MSM with genotypes other than the primary infection suggests original infection confers partial immunity to similar genotype. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 STARTVerso 4: Faldaprevir Plus Peginterferon/Ribavirin Associated With High Early Virologic Response Rate in HIV/Genotype 1 HCV–Coinfected Patients In interim analysis, 82% of HCV treatment–naive patients and 91% of previous relapsers coinfected with HIV attained HCV RNA below lower limit of quantitation with faldaprevir plus peginterferon/ribavirin at Week 12 of therapy. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 Random Biopsy Increases Number of High-Grade Squamous Intraepithelial Lesions Detected by High-Resolution Anoscopy and Improves Diagnostic Rate in Patients With Suspected Anal Squamous Cell Cancer Increased risk of HSILs detected by random biopsy was associated with greater number of HSILs detected by standard biopsy, whereas oncogenic HPV infection, provider/venue were associated with increased risk of HSILs detected by random or standard biopsy. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 RIFAQUIN Trial: High-Dose Rifapentine 1200 mg Once Weekly Plus Moxifloxacin in Continuation Phase Safe, Noninferior to Control in Patients With New Pulmonary TB A 4-month regimen with twice-weekly rifapentine 900 mg plus moxifloxacin in the continuation phase was safe but demonstrated inferior efficacy compared with an isoniazid-containing control regimen. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 10 of 17 Shown Show 7 More Loading...	Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC Contact Info Educational grants provided by: Educational grants support only the CME-certified components of this program.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Source: 2013 Conference on Retroviruses and Opportunistic Infections*

Conference Program

Latest Content